header logo image


Page 32«..1020..31323334..4050..»

Archive for the ‘Blindness’ Category

PROFILE 2020 – Mission to Serve: Ironton Lions Club has been serving community for nearly a century – The Tribune – Ironton Tribune

Sunday, March 1st, 2020

The Ironton Lions Club was organized by Fred T. Davis, receiving its charter on Dec. 19, 1923.

The Ironton Lions Club was the 18th club chartered in the State of Ohio, and its first president was Howard E. Unrue. The Ironton club now consists of 30 members and the club motto is WE SERVE.

Over the years, the Ironton Lions Club has raised funds through various activities such as a minstrel show, war bond drives, a beauty pageant, haunted houses, haunted tunnel, golf tournaments and the sale of light bulbs and other items.

The funds raised by these efforts were used to support the Lions contributions to the local community, as well as the Lions activities at the district, state and international levels. The Ironton Lions Club annually distributes approximately $10,000 in aid and charity.

Locally, the Ironton Lions have provided monetary support to the Ironton City Mission, the Briggs Lawrence County Library Vision Impaired Center, Open Door School, scholarships, Project LifeSaver, local food banks, Pilot Dogs of Ohio, Ironton Little League, annual Halloween, Christmas and Memorial Day parades, Community Hospice, eye tests and funding for childrens eyeglasses and other worthwhile projects.

The Ironton Lions Club is active in a wide range of blindness and diabetes prevention endeavors at the local, state and international levels.

The Ironton Lions Club also supports The Lions Quest Program, in partnership with the Symmes Valley Multi-Level School, to teach age appropriate positive youth civic development programs.

STORY, BRENT PYLES | PHOTOS, HEATH HARRISON, SUBMITTED

Read the original post:
PROFILE 2020 - Mission to Serve: Ironton Lions Club has been serving community for nearly a century - The Tribune - Ironton Tribune

Read More...

Eminent Ophthalmologist VK Raju honored by Egyptian Ophthalmology Society – The Indian Panorama

Sunday, March 1st, 2020

Founder-President of Eye Foundation of America Dr. VK Raju was honored by the Egyptian Ophthalmology Society with a medal for his contribution in the field of prevention of blindness among children worldwide

CAIRO (TIP): Dr. VK Raju, an eminent ophthalmologist based in Morgan Town, West Virginia, USA was invited to Cairo by the Egyptian Ophthalmology Society to speak on childhood blindness. He lectured on difficult cataract surgery, prevention of blindness in premature children. The condition is called ROP (retinopathy of prematurity). If premature babies are given too much oxygen, it can be harmful. It leads to bleeding in the eye and causes permanent blindness. The good news is it can be prevented by laser treatment. Early recognition is the key.

Dr. Raju who is Founder and President of the Eye Foundation of America is a passionate crusader for prevention of avoidable childhood blindness. His passion takes him to many parts of the world, particularly to his country of origin India where he has set up a hospital and eye institute in Rajahmundry, Andhra Pradesh. At the Goutami Eye Institute, Rajahmundry, a dedicated staff serves a large community, particularly rural.

Dr. VK Raju is internationally recognized and has been honored by many organizations. Only this January, Rotary Club of Calcutta, the oldest Rotary club, at their centenary celebrations, honored Dr. Raju for his tremendous contribution.

Visit link:
Eminent Ophthalmologist VK Raju honored by Egyptian Ophthalmology Society - The Indian Panorama

Read More...

Gene therapy shows promise in tackling common cause of childhood blindness – Mirage News

Sunday, March 1st, 2020

The results of a first-in-human clinical trial of gene therapy to treat a common cause of genetic blindness have shown partial reversal of sight loss in some patients.

X-linked retinitis pigmentosa, caused by mutations in RPGR gene, is the most common cause of blindness in young people. The inherited mutations lead to degeneration of light sensitive cells (photoreceptors) beginning in early childhood leading to severe sight loss.

Until now there has been no treatment for this disease. Gene therapy using viral vectors to deliver a healthy copy of a mutated gene into affected cells aims to slow down the degeneration and preserve visual function.

However, the RPGR gene has an unusual genetic code which makes it unstable to work with in the laboratory and until now difficult to translate into human trials.

Scientists at the University of Oxford reprogrammed the genetic code of the RPGR gene to make it more stable, providing the basis for this first-in-human retinal gene therapy.

The international trial, led by Professor Robert MacLaren, was sponsored by Biogen Inc., with support from the NIHR Oxford Biomedical Research Centre.

Eighteen patients in total were treated with increasing doses of the vector carrying an RPGR gene in which the DNA had been altered, but in a manner that still allowed correct production of the missing protein.

Other trial sites included the Manchester Royal Eye Infirmary and the Bascom Palmer Eye Institute in Miami.

The research teams findings are published in the journal Nature Medicine.

Professor MacLaren, Consultant Ophthalmologist at the Oxford Eye Hospital, commented: We are delighted with the early results of this clinical trial for a degenerative eye disease. It is becoming more apparent to us that novel genetic therapies, when working, lead to a clear improvement in neuronal function, which holds great hope for a variety of other degenerative conditions that have a genetic basis.

Once again, we should take note that this highly successful international gene therapy clinical trial originated in the NHS by applying science that was previously developed in a project funded in the UK by the Medical Research Council.

The early results from the study showed that the treatment was safe and six patients who received mid doses of the vector had unexpected improvements in their peripheral vision beginning as early as one month after the treatment.

One of Professor MacLarens patients, Kurtis Lonie, said: When my mum spotted the trial in an RNIB newsletter I felt so hopeful about what I was reading. At this stage in my life I was struggling deeply with what I thought my life would become. The speed of my conditions degeneration was unknown so I had no choice but to apply and do whatever I could to hopefully help others in the future, as well as myself.

After undergoing tests and screening, Kurtis was given the choice of which eye he wanted to be treated, and he opted for the one with worse vision.

About a month after the treatment my vision was beginning to return in the treated eye. The sharpness and depth of colours I was slowly beginning to see were so clear and attractive. My visual field exploded and I could see so much more at once than ever before in that eye. Before long, the eye was undoubtedly better than the untreated eye.

The results have been nothing short of astonishing and life changing for me, I really hope this trial is approved and they can treat what once was my better eye.

This improvement in peripheral vision experienced by some patients is believed to relate to regeneration of outer retinal structures following successful gene therapy and has implications for the development of similar gene-based treatments for many other retinal degenerations.

Nightstar Therapeutics was a University of Oxford spinout company founded in 2014 and listed on NASDAQ in 2017. The RPGR gene therapy developed in Oxford was licenced to Nightstar in order to set up the international clinical trial.

In 2018 Nightstar Therapeutics was acquired by the large US biotech company Biogen, in what was one of the biggest buyouts of a British biotechnology company to date.

The funding raised combined with the successful start of the clinical trial has highlighted the huge potential for academic collaborations between UK universities, the Department of Health and the global biotechnology sector. This has been a key long term strategic aim of the NHS funding directed through the National Institute for Health care Research (NIHR).

Link:
Gene therapy shows promise in tackling common cause of childhood blindness - Mirage News

Read More...

Katsina Has 25,000 Blind Persons, Says Foundation – THISDAY Newspapers

Sunday, March 1st, 2020

By Francis Sardauna

A United Arab Emirates (UAE) based non-governmental organiSation, Noor Dubai Foundation on Friday revealed that Katsina State has 25,000 blind persons with only four ophthalmologists spearheading its eye care centre.

Pained by the menace, the charitable organisation in collaboration with the state government, said it had inaugurated a four-year integrated and sustainable eye care programme to improve quality of life and socioeconomic status of the affected persons.

The representative of the foundation, Dr. Rabiu Mansour, who disclosed this to journalists in Katsina while speaking on the achievements of the programme, said six million Katsina citizens were expected to benefit from the programme within the period under review.

He explained that the foundation, which commenced the programme in October 2019, had so far conducted 1,039 successful cataract surgeries and eye screening for 5,238 patients in Katsina, Daura and Funtua general hospitals within four months.

He reiterated that 2,313 visually impaired persons had been treated with either medications or eye glasses, six ophthalmologists and optometrists and one optician had been employed to boost efficient service delivery.

Katsina state has over 25,000 blind people and another 100,000 people with some visual loss, but there are only four ophthalmologists to cater for this population. Currently only about 10 to15 per cent of eye care services are being covered in the state.

In line with Noor Dubai Foundations new strategic plan, it set up a four- year (2019-2023) integrated and sustainable comprehensive eye care programme in partnership with Katsina state government. In addition, a Nigerian office of the Noor Dubai Foundation have been set up in Katsina.

The programme is aim at improving quality of life and socioeconomic status of people of the state through improved access to quality eye care. It will cost about $2 million with the Katsina state government contributing additional 20 per cent in kind.

We intend to conduct cataract surgeries for 12,000 people to restore their sights and 37,000 people are to be screened and treated for eye diseases. While 320,000 school children will also undergo eye screening and treatment. And 1,000 people with permanent visual loss will be rehabilitated, he added.

In his remarks, the State Commissioner for Health, Yakubu Nuhu Danji, said about 4,000 visually impaired people were consulted and 2,000 have been treated by the foundation.

While admitting that the state has 25,000 people suffering from blindness, the commissioner said the alliance between state government and the foundation would eradicate the impediment.

He said: As you are all aware, Katsina state has 25,000 people suffering from blindness and right now we only have four ophthalmologists manning the eye centre we have.

Danja said the state government had inaugurated an awareness committee to educate the residents, particularly rural dwellers on the need to patronise the eye care centres to prevent them from impairment.

Meanwhile, the foundation, established by the Vice President, Prime Minister of UAE and the ruler of Dubai, Sheikh Mohammed bin Rashid Al-Maktoum in 2010 focused on prevention of blindness and visual impairment globally.

Over 27 million people in 18 countries across Africa and Asia were said to have benefited from the free treatment and prevention programmes conducted by the Foundation.

Go here to see the original:
Katsina Has 25,000 Blind Persons, Says Foundation - THISDAY Newspapers

Read More...

World Rare Disease Day: Are they more common than you think? – Outlook India

Sunday, March 1st, 2020

World Rare Disease Day: Are they more common than you think?

New Delhi, Feb 29 (IANSlife) World Rare Disease Day is observed every year on the last day of February.

A Rare Disease is also known as Orphan Disease and is said to affect a small percentage of the population. It presents a countless number of challenges for patients and their family members, including the time it takes to obtain a correct diagnosis.

Although cancer and heart disease get plenty of media attention, the impact and reach of rare diseases vary significantly. One of the rare diseases may affect only a handful of patients, while another disease could affect many. At times, Rare Diseases are difficult to diagnose because of its nonspecific symptoms and because they''re so unusual.

It is said that 1 in 20 Indians is affected by a Rare Disease. According to Indian Society for Clinical Research (ISCR). 70 million in India and 350 million people around the world suffer from rare diseases.

There are more than 7,000 distinct types of Rare and Genetic diseases and it has impacted more people than Cancer and AIDS combined and most of which are progressive, life-threatening, and chronically debilitating conditions and 80 percent of these rare diseases have a genetic origin.

Dr. Mayuri.K.S., Consultant Microbiologist and Infection Control Officer, SPARSH Hospital, Bengaluru shares few types of rare diseases:

Acanthamoeba keratitis

Acanthamoeba keratitis is a vision-threatening rare disease which causes parasitic infection and can be seen most often in contact lens wearers. It is found ubiquitously in soil and water and can cause infections of the skin, eyes, and central nervous system.

This infection of the cornea is difficult to treat with conventional medications. It may lead to permanent visual impairment and blindness in some cases because of damage to the clear portion of the front of the eye called the cornea or through damage to other structures important to one''s vision.

Creutzfeldt-Jakob disease (CJD)

Creutzfeldt-Jakob disease is also known as Classic Creutzfeldt-Jakob disease. CJD is a fatal degenerative brain disorder which is believed to be caused by a protein known as prions. The early symptoms include visual disturbances, memory problems, behavioural changes and also poor coordination.

The later symptoms include weakness, involuntary movements, blindness, dementia and coma. About 70 percent of people die within a year of diagnosis as there is no specific treatment for CJD.

Cysticercosis

Cysticercosis is a rare infectious disease. It is a tissue infection which is caused by the tapeworm present in the pork. It is known to cause neurocysticercosis which affects the brain and can cause neurological symptoms. Individuals suffering from this rare disease may have few or no symptoms for years.

Cysticercosis is usually acquired by eating contaminated food. One of the major sources is said to be uncooked vegetables. Drinking water contaminated by tapeworm eggs from human feces is also one of the main reasons to cause the infection.

Mucormycosis

Mucormycosis is caused by fungi in the order Mucorales. And they are generally the species in the Mucor, Rhizopus, Absidia and Cunninghamella. The disease is often characterized by hyphae growing in and around blood vessels and can be potentially life-threatening in diabetic or severely immune-compromised individuals.

Mucormycosis and zygomycosis are sometimes used interchangeably. It frequently infects the sinuses and the brain. While infection of the oral cavity or brain is the most common form of mucormycosis and it enters the body through a cut in the skin. The fungus can also infect other body areas such as the gastrointestinal tract, other organ systems and in rare cases, the maxilla may be affected by mucormycosis.

Fungal infections are usually prevented by the rich blood vessel supply of maxillofacial areas. Although more virulent fungi responsible for mucormycosis can often overcome this difficulty.

Naegleriasis

It is also known as PAM - Primary Amoebic Meningoencephalitis. This rare disease is an almost invariably fatal infection of the brain by the free-living unicellular eukaryote Naegleria fowleri. Symptoms are meningitis which includes headache, fever, nausea, vomiting, a stiff neck, confusion, hallucinations and seizures. Symptoms progress rapidly over five days and death usually results within one-to-two weeks of symptoms.

Nocardiosis

Nocardiosis is an infectious disease affecting either systemic nocardiosis which is the whole body or pulmonary nocardiosis which are the human lungs. It is caused due to an infection by a bacterium of the genus Nocardia, most commonly Nocardia asteroides or Nocardia brasiliensis. It is most commonly seen in adult males, especially those with a weak immune system.

Patients with brain Nocardia infection, mortality exceeds 80%, in other forms, mortality is 50%, even with appropriate therapy. It is one of several conditions that have been called "the great imitator" and Cutaneous nocardiosis commonly occurs in immunocompetent hosts.

Rat-bite fever

It is an acute, febrile human illness caused by bacteria transmitted by rodents, in most cases, which is passed from rodent to humans by the rodent''s urine or mucous secretions. Alternative names for this rare disease include streptobacillary fever, streptobacillosis, spirillary fever, bogger, and epidemic arthritic erythema. It is spread by infected rodents and can be caused by two specific types of bacteria.

In some of the cases are patients were diagnosed after they were exposed to the urine or bodily secretions of an infected animal. These secretions can come from the various body parts like mouth, nose or eyes of the rodent and majority of cases are due to the animal''s bite. It is also said to be transmitted through food or water contaminated with rat feces or urine.

Other animals that can be infected with this disease are household pets, weasels, gerbils and squirrels. It is important to quickly wash and cleanse the wound area thoroughly with an antiseptic solution to reduce the risk if a person is bitten by a rodent.

Cat-scratch disease (CSD)

It is caused due to scratching or biting of a cat. Typically include a non-painful bump or blister at the site of injury caused due to scratch or bite. Within 3-14 days following infection and the individual may feel tired, have a fever and headache.

Cat scratch disease is caused by the bacterium Bartonella henselae spread by the cat''s saliva. Young cats pose a greater risk than older cats. Diagnosis is generally based on symptoms but confirmed through blood tests.

The primary treatment is supportive. Recovery occurs within four months but can require a year. About 1 in 10,000 people are affected and it is found to be more common in children. These diseases may seem to be rare, but there is a significant figure that highlights just how many people are living with it but that gets a little attention due to their singularity. The challenges they face are common to millions of people across the world.

There is much work to be done to spread the awareness of rare diseases and also to improve the diagnosis and treatment of rare diseases. Only less than 5 percent of the 7000 rare diseases have approved therapies. On average, the rare disease patient waits about five years from symptom onset to accurate diagnosis.

In order to tackle the challenges that people living with a rare disease and their families face every day, awareness campaigns should focus on bridging all the gaps in the coordination between medical, social and support services.

--IANS

lh/adr/sj/

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: IANS

Continue reading here:
World Rare Disease Day: Are they more common than you think? - Outlook India

Read More...

Microsoft Invests In A New AI For Health Initiative – Forbes

Sunday, March 1st, 2020

As one of the richest people in the world, Bill Gates is known for contributing to global health through the Gates Foundation. As his biggest legacy, Microsoft is also moving in the same direction. The company is actively involved in helping the worlds population overcome some of the most challenging health problems and concerns.

Microsoft recently announced a new healthcare initiative known as AI for Health, a program worth over 40 million dollars. AI for Health evolved out of the AI for Good Program, which offers general aid to the less fortunate around the world.

The new initiative will primarily focus on health-related problems and the integration of AI and tech solutions. The main goal behind AI for Health is to directly research the impact of AI in the medical field, as well as develop algorithms for automatic detection of diseases and other medical operations. Besides building new solutions, the program will also work toward making these technologies more available worldwide.

AI for Health is a philanthropic initiative that complements our broader work in Microsoft Healthcare. We will support specific nonprofits and academic collaboration with Microsofts leading data scientists, access to best-in-class AI tools and cloud computing, and select cash grants, wrote Microsofts John Kahan in the official announcement of the new initiative.

How AI Can Aid the Healthcare Industry

Even to this day, underdeveloped countries are very far from being able to afford and implement AI technology in medical treatments. There is no doubt that modern healthcare solutions are distributed unevenly, leaving the population of some countries to die of diseases that dont even exist in modern countries anymore.

Even though AI cannot directly aid in distributing healthcare evenly, research in this field can help provide more affordable solutions. For example, AI can be used to build reliable screening systems for disease detection, more specifically for diabetic retinopathy which leads to blindness if not treated in time. AI-based systems would serve as cheaper and easier diagnostic processes for patients around the world.

Microsofts program aims to encourage the best experts in the field to actively help engineer and deploy such solutions. There is no doubt that the companys monetary investment is going to help push this project to the right direction. The company has already made several important partnerships with parties that can benefit from this research.

The AI-oriented research will look for solutions for various diseases and issues including tuberculosis, maternal mortality, and even cancer. It is also important to mention that Microsoft has decided that the new initiative wont be open for public organizations. Instead, it will be working directly with the privately chosen non profits and research organizations.

Go here to read the rest:
Microsoft Invests In A New AI For Health Initiative - Forbes

Read More...

Cynthia Taylor: Speaker will address the question Can we all get along? – The Augusta Chronicle

Sunday, March 1st, 2020

A mutually hurting stalemate. That seems to be a good description of where we are as a country and its tearing at our souls. This doesnt just apply to our political divisions, which seem insurmountable, but also to the racial divide in our country.

Nearly 30 years ago, riots broke out in Los Angeles over the acquittal of police officers who had been accused of savagely beating Rodney King. At the height of the riots, an anguished King appeared on television asking the haunting question, Can we all get along? That question is written on his gravestone.

Apparently, the answer seems to be, No, we cant get along. Or can we?

The Rev. Gary Mason, a Methodist minister from Northern Ireland, has spent his life working on how to answer the question, Can we all get along? The divisions in that country were as deep or deeper than anything were currently experiencing in America. And yet, Mason was one of those who became involved in the peace process in Northern Ireland that has led to reconciliation. He was recognized by Queen Elizabeth for his work in the peace process.

At the Last Supper, Jesus prayed that we all may be one. But becoming one doesnt mean its easy nor does it mean we all end up thinking alike. Like those in Northern Ireland, we dont know how to put down our weapons. Here our weapons are words and actions that demonize others, making them seem less than children of God, made in the image of God.

Such violence has led to what Mason calls the mutually hurting stalemate. Those of us who follow Jesus call him the Prince of Peace, but we dont always live into being peacemakers ourselves. We dont know how to disagree well without being disagreeable. We dont know how to have the hard conversations with those who differ from ourselves.

We have just begun the season of Lent and, in my tradition, it began this past week with Ash Wednesday a service of repentance and reconciliation with God and others.

In part of the service called The Litany of Penitence, we ask God to accept our repentance for the wrongs we have done; for our blindness to human need and suffering for all false judgments and for our prejudice and contempt toward those who differ from us.

True repentance is not just acknowledging all the ways we have fallen short but living into a new way of being, a new way of life.

Gary Masons life work is teaching how to live into a new way of being and doing the hard, hard work of reconciliation. Its not wrapping ourselves in a cocoon of naivety that peacemaking is easy. Its not. But, sweet Lord, is it ever necessary, now more than ever.

Mason will be in Augusta for a series of events on Reconciliation: Healing the Hurt. These will be held at Church of the Holy Comforter, 473 Furys Ferry Road, Martinez. The first is a Community Forum on Saturday, March 7 from 6-8 p.m. Then he will be teaching and preaching Sunday, March 8, beginning at 9:15 a.m. in the Rectors Forum and worship at 10:30 a.m. All events are free and open to the public.

After his work in Northern Ireland, Mason started Rethinking Conflict, an institute devoted to social justice, conflict transformation, peace building and addressing religious fundamentalism. He is an adjunct professor at Candler School of Theology and the Kennedy Institute for Conflict Intervention in Maynooth University, Ireland.

Can we all get along? How will you answer that question?

The Rev. Cynthia Taylor is the pastor of the Church of the Holy Comforter in Martinez.

Visit link:
Cynthia Taylor: Speaker will address the question Can we all get along? - The Augusta Chronicle

Read More...

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential – The Motley Fool

Sunday, March 1st, 2020

There are a lot of promising stocks out there for investors to choose from. However, if you're looking for companies with the most growth potential, the world of small-cap stocks is one of the best places to look.

In particular, biotech stocks are very well known for having tremendous upside potential. New drug candidates can easily bring in billions in revenue for companies, should they prove to be a success. However, many of these stocks are quite risky investments, especially since a good number are barely reporting any revenue figures whatsoever.

If you're comfortable with these types of investments, here are three high-risk, high-reward stocks that you should keep your eye out for in the future.

Image source: Getty Images.

Gene editing is an incredibly promising market that many biotech investors are paying close attention to. There are plenty of genetic disorders out there that might not be treatable with today's technology, but could be cured with the use of gene editing treatments in the future. Editas Medicine (NASDAQ:EDIT) is one company in this space that boasts a number of promising drug candidates, and it also has an impressive patent portfolio.

Editas's flagship drug candidate is EDIT-101, a treatment for a rare form of blindness in children called leber congenital amaurosis (LCA), which leads to a loss of eyesight as the retina fails to function properly. Although LCA is rare, affecting only 2 to 3 newborns per 100,000, the good news for Editas is that not many companies out there are trying to treat this condition.

Currently, the only other treatment for LCA is Luxturna, a drug developed by Spark Therapeutics. Besides the massive $850,000 price tag (or $425,000 for just one eye), Luxturna only works for a very specific variant of LCA, with most of the patient population not qualifying for the treatment.

EDIT-101, on the other hand, would be available for all LCA patients. Assuming EDIT-101 is priced somewhere near Luxturna's price point, the company would need to treat just 1,300 LCA patients annually for EDIT-101 to make over $1 billion in revenue. Considering that Editas made only $3.8 million in its recent third-quarter 2019 results, it's easy to see how positive results from this one drug alone could catapult the company's stock to new highs.

EDIT-101 is currently undergoing early clinical trials and likely won't be available for a couple of years at the earliest, if not longer. There is one other small-cap biotech stock,ProQR Therapeutics, working on a possible LCA treatment,but it's doing so without any backing from other, larger pharmaceutical giants.

In comparison, Editas has partnered with Allerganto help commercialize EDIT-101 should it become a success. Having a big partner such as Allergan with strong connections in the industry is a big advantage for any small-cap biotech stock looking to market its candidates.

Back in early January, I argued that Puma Biotechnology (NASDAQ:PBYI) was far from a good investment. By the end of 2019, the stock had lost around95% of its market capin comparison to where it was just a couple years before. Coupled with uncertainties regarding the appeal of its main drug, Puma's future looked very uncertain.

However, the stock has seen a surprising comeback over the past couple of months, surging by about 22%. The weird thing is that there's not much in the way of news to justify this rise. Puma's recent fourth-quarter results were pretty bad, with revenue down 11.5% to $62.9 million from last year, although this still slightly beat out analyst expectations.

Image source: Getty Images.

Puma's main treatment is its cancer drug Nerlynx, which is given to adults who have early stage HER2-positive breast cancer (a form of the disease that tests positive for a protein called human epidermal growth factor receptor 2, or HER2, which promotes the growth of cancer cells). The problem is that Nerlynx causes severe diarrhea as a side effect, which has led to a startlingly high discontinuation rate among patients.

While the company is making efforts to tackle this problem, such as providing vouchers for anti-diarrheal medications, it's still uncertain whether Nerlynx sales will recover.

The silver lining behind all this is that Puma is incredibly cheap, with the stock currently trading at a measly 1.9 price-to-sales ratio. While I don't think there's much hope for Nerlynx as a blockbuster cancer drug, there's a solid chance that Puma could become a buyout target for another, larger biotech company, considering how cheap its stock is. Should this happen, shareholders would see a significant surge in Puma's stock price following the news.

If you want to buy in anticipation of this, however, it might be best to wait for the stock to dip back down in value again. Considering that this recent surge doesn't seem backed by anything substantial in terms of news or catalysts, it wouldn't be surprising for the stock to tumble down once more. Long-term, however, Puma has a good shot at becoming an acquisition target, and as such, has a fair bit of upside potential in 2020.

Xenon Pharmaceuticals (NASDAQ:XENE) is a small-cap biotech stock that, by the end of the year, could easily have three late-stage drug candidates in its pipeline.

Its flagship drug, XEN496, is one of Xenon's promising epilepsy treatments, and is on the cusp of entering phase 3 trials.

XEN1101 is another epilepsy candidate that's currently in phase 2 trials, while XEN007 is a candidate also in phase 2 trials and is meant as a treatment for orphan neurological indications, which includes symptoms such as migraines, vertigo, and certain types of epilepsy.

Xenon has also grabbed the attention of a number of pharmaceutical giants interested in its drug candidates. Merckand Rocheare the two standouts, while Flexion Therapeuticsand Neurocrine Bioscienceshave also signed strategic partnerships with Xenon.

These agreements have helped finance Xenon's clinical development, with the company receiving $50 million in cash and equity from Neurocrine back in December.

Another one of Xenon's epilepsy drug candidates, XEN901, is eligible for up to $1.7 billion in milestone payments from Neurocrine, should the drug prove to be a success. In comparison, Xenon reported just $3.5 million in third-quarter revenue.

With that much potential upside from just one of Xenon's epilepsy candidates, the optimism surrounding this specific biotech stock is justifiably high.

See the article here:
3 High-Risk, High-Reward Stocks That Have Massive Upside Potential - The Motley Fool

Read More...

Makers of adulterated wine ask customers to check their bottles – The Brussels Times

Sunday, March 1st, 2020

Photo from Antwerp prosecutor's office

The Dutch makers of the wine branded Black & Bianco have called on anyone who bought the wine to check the bottle to see if it has been tampered with.

Earlier in the week it was announced that a Belgian woman from Puurs in Antwerp province had died after drinking a small amount of the wine. At autopsy it was found that the wine had been adulterated with large doses of MDMA or ecstasy and a similar illicit drug MDA.

The bottle she drank from did not have the brands trademark black cork covered with a black foil bearing the companys name and logo. Police hypothesised the bottle was one of several adulterated as a method of smuggling the rugs into Belgium illicitly.

However no new cases have come to light, despite the fact that the victim died in December, and the news this week was widely covered.

In addition, it is not clear how the bottle could have escaped the hands of the smugglers themselves, and finished with a legitimate client in Belgium.

The wine Black & Bianco RED Merlot Cabernet Sauvignon is not sold in Belgium other than online, although it is on open sale in the Netherlands.

Meanwhile a number of the webshops that had previously carried the wine in question have withdrawn it from sale, while the brand owner said the wine is absolutely still drinkable so long as the cork has not been tampered with.

The telephone here doesnt stop ringing. Many of our clients are naturally asking questions. They want to know whats going on, and if there are possibly other bottles that are not right, said owner Coen Scholders.

I can understand their concern, but our wine can absolutely still be drunk. There is for the time being no indication that more of our bottles have been tampered with and are still in circulation.

Meanwhile it has been revealed that the woman who died was an employee of Finshop, a shop operated by the federal finance ministry which sells off goods seized by customs officers to the general public. Three years ago some customers had to be rushed to hospital after a bottle of wine on sale in one of the shops turned out to contain MDMA in methanol a dangerous form of alcohol that can cause blindness and death.

Since then, however, Finshop stores no longer sell wine to members of the public, the ministry said.

Ministry spokesperson Francis Adyns said it was unlikely the woman had come across the wine in the shop and taken it home. The Antwerp prosecutors office said it had no information to suggest that might have happened, but that all avenues of investigation are being looked at.

Alan HopeThe Brussels Times

Read the original here:
Makers of adulterated wine ask customers to check their bottles - The Brussels Times

Read More...

Trending News: Ophthalmic Condition Linked to Blindness in Diabetes May Indicate Stroke Risk – Pharmacy Times

Friday, February 14th, 2020

Trending News: Ophthalmic Condition Linked to Blindness in Diabetes May Indicate Stroke Risk

A new phase 1 trial has demonstrated that a PRIMVAC placental malaria vaccine candidate is safe, immunogenic, and induced functional antibodies in volunteers, according to Contagion Live. The study, which marked the first in-human trial of the vaccine candidate, involved a randomized, double-blind trial in 2 staggered phase taking place between April 2016 and July 2017. Antibody titers increased with each successive dose and seroconversion was observed in all women who received the vaccination.

An ophthalmic condition linked to blindness in diabetes could serve as an additional indicator of increased stroke risk, according to HCP Live. An analysis of more than 2500 patients revealed that those who had diabetic retinopathy had an increased risk of stroke compared with patients without diabetes. The study also showed that having diabetic retinopathy was associated with a 60% higher risk of stroke compared with patients with diabetes without the ophthalmic condition. The study authors feel that more aggressive treatment for patients with a risk of stroke and who have been diagnosed with diabetic retinopathy may be warranted to reduce risk.

Visit link:
Trending News: Ophthalmic Condition Linked to Blindness in Diabetes May Indicate Stroke Risk - Pharmacy Times

Read More...

Blindness from cataracts on the rise in Sudan – Radio Dabanga

Friday, February 14th, 2020

Ophthalmologists announced an increase of blindness in Sudan during a workshop in Khartoum on Saturday. The reason: it is impossible to reach the marginalised areas of the country to conduct cataract operations there.

Cataract is the main cause of blindness in Sudan. It most commonly affects adults as a result of ageing.

Cataract surgery involves replacing the cloudy lens inside an eye with an artificial one. Cataracts usually get slowly worse over time. Surgery to replace the cloudy lens is the only way to improve eyesight. The operation has a high success rate.

The Sudanese ophthalmologists said that there are patients who cannot cover the costs of the operations because of poverty or dont know they can be treated.

The ophthalmologists pointed out that there are no eye hospitals in several states. Most eye operations and eye treatment are concentrated in Khartoum and the state capitals.

Radio Dabangas editorial independence means that we can continue to provide factual updates about politicaldevelopments to Sudanese and international actors, educate people about how to avoid outbreaks of infectious diseases, and provide a window to the world for those in all corners of Sudan.Support Radio Dabanga for as little as 2.50, the equivalent of a cup of coffee.

The rest is here:
Blindness from cataracts on the rise in Sudan - Radio Dabanga

Read More...

Biomarkers of inflammation and oxidative stress in ophthalmic disorders. – Physician’s Weekly

Friday, February 14th, 2020

The review article focuses on free radicals and oxidative stress involved in ophthalmological diseases such as retinopathy, cataract, glaucoma, etc. Oxidative stress is considered as a key factor involved in the pathology of many chronic diseases including ophthalmic complication and inflammatory process. Oxidative stress and inflammation are closely related pathophysiological processes and are simultaneously found in many pathological conditions. The free radicals produced oxidize cellular components such as lipids and phospholipids leading to lipid peroxidation and trigger the onset of retinopathy. Cataract is a significant cause of visual disability and it is proposed that the high incidence is related to oxidative stress induced by continued intraocular penetration of light and consequent photochemical generation of free radical oxidants. Glaucoma is the leading cause of irreversible blindness and comprises a group of diseases characterized by progressive optic nerve degeneration. Oxidative injury and altered antioxidant defense mechanisms in glaucoma appear to play a role in the pathophysiology of glaucomatous neurodegeneration that is characterized by death of retinal ganglion cells. The UVB radiations through this way may cause a number of diseases like photo-keratitis, pterygium, damage to epithelium, edema, and corneal cell apoptosis.: ROS: reactive oxygen species; RNS: reactive nitrogen species; O: superoxide anion; HO: hydrogen peroxide;. OH: hydroxyl radicals; ONOO, ONO peroxynitrite; NO: nitric oxide; IOP: intraocular pressure; RGC: retinal ganglion cells. WHO: World Health Organization; IAPB: International Agency for the Prevention of Blindness.

See the original post here:
Biomarkers of inflammation and oxidative stress in ophthalmic disorders. - Physician's Weekly

Read More...

The Offensiveness Of Color-Blindness In America. – ThyBlackMan

Friday, February 14th, 2020

You are here: Home / News / The Offensiveness Of Color-Blindness In America.Like

LikeLoveHahaWowSadAngry

1

(ThyBlackMan.com) It is difficult to argue against the fact that those among us who insist that they do not see color are balanced between being well-meaning and nave. My familiarity with such types is best expressed by an unemotional reaction to their pleadings for me to join the ranks of the historically illiterate.

Despite what the color-blind brigade believes, I understand that their emotional state vacillates between moments of frustration and uncontrollable white-rage. This matter is at the forefront of my mind due to a recent Facebook posting from what appears to be a well-meaning White lady who insists that she does not see color.

As stated above, I understand that her passion flows from a desperate desire to see all of her countrymen living in harmony. However, she fails to comprehend a fact provided by a former student who posited that America will never get past Race. It is who we are. So how can we ever get past it?

Although I agreed with my students assertion that impressively echoes W.E.B. DuBois ominous warning that the color line will be the problem of the twentieth century, I realized that the source of this post vehemently disagrees with such sensibility.

Experience has taught me that the color-blind brigade wishes for a simpler time that never existed. A cursory examination of their beliefs reveals that We never were what they thought we used to be. Many of their numbers have foolishly advanced the assertion that If we stopped talking about Race it would simply go away!!!!!

I can only imagine that if my exchange with the lady who created the alluded to post were in-person and not via social media that she would scream that I dont see color!!!!! I only see human beings to my face.

Im convinced that the color-blind argument, albeit well-meaning, primarily results from what can only be termed a loose use of language. Put simply; these people do not realize what they are actually saying in their fits of rage. If provided the opportunity to meet with representatives of the color-blind brigade, I would ask them to provide a description of me. I am certain that they would avoid physical descriptors such as my status as an African-American male.

What members of the color-blind brigade fail to consider is that their steadfast denial of physical traits is not complementary to those they are seeking to aid in their color-blindness. It is extremely insulting. They are in effect saying that they must deny a portion of my being to accept me or you. If provided the opportunity, I would advise the color-blind brigade to abandon their standard phraseology in favor of the following.

I recognize your racial identity; however, I do not ascribe any negative characteristics to you because of it.

Trust me when I say that this slight verbal alteration will make a major difference to all and hopefully open a long-overdue dialogue about Race in America.

Staff Writer;Dr. James Thomas Jones III

Official website;http://www.ManhoodRaceCulture.com

One may also connect with this brother viaTwitter;DrJamestJones.

Read more:
The Offensiveness Of Color-Blindness In America. - ThyBlackMan

Read More...

This musical charity night raising awareness of cancer and blindness is heading to Penwortham – Lancashire Post

Friday, February 14th, 2020

Sounds Right, a seven-piece band, is playing a charity night at Penwortham Arts Centre "The Venue".

Sounds Right, a seven-piece function band, will entertain music lovers on Saturday, February 29th, at Penwortham Arts Centre "The Venue" in Liverpool Road from 7pm to 10pm.

The event has been organised by Penwortham Town Council in aid of Cancer Research UK and Galloway's Society for the Blind, which is based in Howick House, Penwortham.

Trumpet player Chris Andrew said: "We think it's really important because unfortunately some members of the band have been treated by cancer specialists, so we would like to give something back."

Sounds Right formed nine months ago and comprises ex-military/police officers and cruise ship musicians. Boasting both male and female vocals, the band plays a wide range of genres, including rock and roll, Latin and traditional ballroom, and incorporates the trumpet, trombone, saxophone, keyboard, bass and drums.

Chris added: "We're called Sounds Right because our music sounds right for any occasion. I don't think Penwortham has had an event like this before so it will offer something unique."

For more information, contact Chris on 07968 185922.

The rest is here:
This musical charity night raising awareness of cancer and blindness is heading to Penwortham - Lancashire Post

Read More...

Emirati donates Dh10.5m to campaign to end river blindness – The National

Friday, February 14th, 2020

An Emirati man donated Dh10.5 million to a campaign that aims to end river blindness.

Bader Al Hilali, a philanthropist, made the donation to the Reach Campaign, an Emirates Red Crescent-organised drive that targets neglected tropical diseases, which are little known in the wider world but devastating for sufferers.

"It gives me immense pride to support the Reach Campaign and join its noble goal to end river blindness. I am particularly pleased the campaign launched first in the UAE, further illustrating our culture of generosity and

humanity. I look forward to seeing our community come together to tackle this urgent issue and help improve the lives of millions around the world," Mr Al Hilali said on Wednesday.

The Reach Campaign launched two weeks ago and uses the theme Give 2, Save 2 meaning that a Dh2 donation is enough to provide the medicine and treatment to protect one person against both diseases for an entire year - to encourage donations.

More than 200 million people worldwide require treatment for river blindness, one of the leading causes of preventable blindness. It is caused by repeated bites by black flies that live near flowing water.

Like many neglected tropical diseases, river blindness disproportionately affects the worlds most vulnerable people, trapping their families in cycles of poverty. Most of the cases are found in 31 countries in sub-Saharan Africa.

Proceeds from the campaign will go to the Reaching the Last Mile Fund, which delivers prevention and treatment across seven countries in Africa and the Middle East.

All the information can be found on the Reach website and using the social media handle, @reachtheendorg.

Updated: February 13, 2020 01:56 PM

Continued here:
Emirati donates Dh10.5m to campaign to end river blindness - The National

Read More...

International team delivers research breakthrough for leading cause of blindness – Mirage News

Friday, February 14th, 2020

Researchers have identified a new protein linked to age-related macular degeneration (AMD) that could offer new hope for the diagnosis and treatment of the disease, which affects more than 1.5 million people in the UK alone.

The research team, made up of scientists from Cardiff University, Queen Mary University of London, the University of Manchester, and Radboud University Medical Center, Nijmegen, found significantly higher levels of a protein called factor H-related protein 4 (FHR-4) in the blood of AMD patients.

Further investigation, using eye tissue donated for medical research, showed the presence of the FHR-4 protein within the macula the specific region of the eye affected by the disease.

The results of the study, published today in Nature Communications, open up new routes for the early diagnosis, by measuring FHR-4 levels in the blood, and suggests therapies targeting this protein could provide promising future treatment options for the disease.

Professor Paul Morgan, an expert in complement biology at Cardiff University, and leader in the development of the antibodies and assays that underpinned this work, said: The collaboration between experts in complement biology, eye disease and genetics across Europe has enabled the accumulation of a robust body of evidence that genetically dictated FHR-4 levels in plasma are an important predictor of risk of developing AMD.

Read this article:
International team delivers research breakthrough for leading cause of blindness - Mirage News

Read More...

Gene therapy offers treatment for X-linked retinitis pigmentosa – Modern Retina

Friday, February 14th, 2020

Abstract / Synopsis:

AAV8-RPGR gene therapy for X-linked retinitis pigmentosa showed early responses to treatment at one month with increased retinal sensitivity with retinal toxicity.

This article was reviewed by Paulo E. Stanga, MD

The results of treatment of X-linked retinitis pigmentosa (XLRP) with AAV8-RPGR gene therapy proved to be early and effective with durable improvements in vision occurring as early as one month following treatment.

XLRP, a rare disease that comprises 10% to 20% of RP worldwide, affects mostly males, and 70% of the cases are caused by RPGR gene mutations and 60% of those are caused by gene mutations in RPGR-ORF15. In this form of RP, the median age of blindness is 45 years, which is younger than the other forms.

Disease progression occurs in stages, with nyctalopia manifesting in the early stage, peripheral visual field constriction in the middle stage, and central visual deterioration and visual loss in the end stage, according to Paulo E. Stanga, MD, professor of Ophthalmology and Retinal Regeneration, Manchester Royal Eye Hospital and University of Manchester, London, UK.

Related: Gene therapy offering hope for retinal, corneal patients

The RPGR mutations cause abnormal transport across the cilium, where RPGR is located, and this abnormal transport results in photoreceptor death.

Obviously, this leads to loss of retinal sensitivity across the visual field and loss of visual acuity, he said.

The treatment that Dr. Stanga and colleagues devised has the goal of correcting the full length of the RPGR-ORF15 mRNA.

We aim for yields of high expression levels that are four times higher than the expression levels of the wild-type RPGR, he explained.

Related: Research targets precision data for gene, cell therapy

Six-month Phase I resultsDr. Stanga and colleagues are currently conducting a two-year dose-escalation clinical trial. The study included men who were 18 years and older with genetically confirmed XLRP. All patients had active disease that was visible bilaterally in the maculas. The study included six cohorts, with the following levels of affect vision: 1, better than light perception; 2 and 3, 34 to 73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; and 4, 5, and 6, greater than 34 ETDRS letters.

The primary endpoint was the incidence of dose-limiting toxicities and treatment-emergent adverse events. The secondary endpoints were the changes in microperimetry, visual stability, and changes in the ellipsoidal zone on spectral-domain optical coherence tomography, Dr. Stanga recounted.

The patients underwent a surgical procedure that included creation of a bleb followed by injection of the virus vector within the bleb.

Related: New vitreoretinal tools advancing surgical outcomes

The investigators evaluated the early effects of changes in the retinal sensitivity in the central retina using microperimetry (Maia, Centervue). The central 16 retinal loci represent 8 degrees of vision; an improvement of five of the central 16 loci equals a 30% improvement in the central visual field. An improvement of 7 dB represents five times greater light sensitivity, he explained.

One month after treatment, Dr. Stanga reported that there was a significant improvement in microperimetry in six of the 12 treated eyes in cohorts 3 to 6 that occurred at one month after vector injection; these cohorts received therapeutic doses. Cohorts 1 and 2, which received subtherapeutic doses, showed no changes.

Cohort 3 showed a mean improvement in the mean retinal sensitivity of 5 to 6 dB in the central 16 retinal loci between the treated and untreated eyes. The improvement became apparent at one month and remained relatively stable at three and six months, Dr. Stanga reported.

According to Dr. Stanga, these changes in retinal sensitivity differed from those observed in untreated eyes in the central 16 retinal loci. The untreated eyes showed decreases in retinal sensitivity over time.

Related: Surgeons provides pearls for handling retinal tears

The microperimetry heat maps also reflected the changes in the treated eyes with enlargement of the sensitive areas.

The investigators also reported that they also determined that the gene therapy with AAV8-RPGR gene therapy for XLRP was generally well tolerated.

No patients left the study and no dose-limiting toxicities were readily apparent.

Transient inflammation developed in the higher cohorts that responded to systemic steroid therapy. Two ocular adverse effects were related to the procedure or drug.

ConclusionsWe demonstrated proof of concept with durable dose-related improvements that appeared as early as one month after treatment across multiple microperimetry analyses, Dr. Stanga concluded. The preliminary efficacy signals were exhibited in cohorts 3 to 6, which responded to the highest doses.

Read more by Lynda Charters

Paulo E. Stanga, MDE: [emailprotected]This article is based on Dr. Stanga's presentation at the American Academy of Ophthalmology 2019 annual meeting. Dr. Stanga has no financial interest in this subject matter.

Read the original here:
Gene therapy offers treatment for X-linked retinitis pigmentosa - Modern Retina

Read More...

Abu Dhabi-based charity seeks Dh2 donation to end river blindness – Gulf News

Friday, February 14th, 2020

The Emirates Red Crescent River Blindness campaign landing page Image Credit: Supplied

Dubai: Emirates Red Crescent (ERC) have launched a campaign to eradicate river blindness, a tropical disease caused by an infection from a parasitic worm, that affects more than 200 million people worldwide.

According to ERC, a donation of Dh2 can provide the medicine and treatment to protect one person from river blindness, lymphatic filariasis and several other co-endemic diseases for the entire year.

Around 21 million people worldwide are infected with river blindness while 217 million people are at risk of contracting the disease and 99 per cent of them live in Sub-Saharan Africa, according to the World Health Organisation (WHO), who have a plan in place to eradicate river blindness in select African countries by 2020.

Like many NTDs (neglected tropical diseases), river blindness disproportionately affects the worlds most vulnerable people, trapping their families in cycles of poverty. It is a threat to human development, especially in Africa. But together we can help end river blindness and ensure a brighter future for millions, said Dr. Mohammad Ateeq Al Falahi, ERC Secretary-General.

The Reach Campaign to combat river blindness in countries that suffer related health challenges reflects the growing role of the UAE and its leadership in fulfilling human and health needs, and improving lives in fragile and troubled areas, he added.

Proceeds from the campaign will go to the Reaching the Last Mile Fund (RLMF) a 10-year US$100 million (Dh367 million) initiative launched in 2017 by His Highness Shaikh Mohammad bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and several supporters.

RLMF delivers prevention and treatment across seven countries in Africa and the Middle East, including Chad, Ethiopia, Mali, Niger, Senegal, Sudan and Yemen. The fund will also be used towards the elimination of co-endemic lymphatic filariasis, which can lead to debilitating elephantiasis.

In 2018, the RLMF ahs delivered over 13.5 million treatments for river blindness and trained 76,000 health care workers to help expand treatment and outreach.

Donations can be made online via Emirates Red Crescent and via SMS, kiosks, ATM machines, and donation boxes. More information can be found via the campaign's website and across social media via @reachtheendorg.

River blindness

River blindness (also known as onchocerciasis) is caused by an infection from a parasitic worm transmitted by blackflies, which breed in fast-flowing streams and rivers. The worms produce larvae that move to the skin, eyes and other organs could lead to debilitating itching, disfiguring skin conditions and sight loss (including irreversible blindness). With these conditions, river blindness has an enormous impact on the lives of those infected by reducing their ability to work and study in school.

In numbers

21 million people worldwide are infected with river blindness217 million are at risk of contracting the disease99 per cent of them live in Sub-Saharan Africa

Read more from the original source:
Abu Dhabi-based charity seeks Dh2 donation to end river blindness - Gulf News

Read More...

Mutation Spectrum of Stickler Syndrome Type I and Genotype-phenotype Analysis in East Asian Population: a systematic review. – Physician’s Weekly

Friday, February 14th, 2020

Stickler syndrome is the most common genetic cause of rhegmatogenous retinal detachment (RRD) in children, and has a high risk of blindness. Type I (STL1) is the most common subtype, caused by COL2A1 mutations. This study aims to analyze the mutation spectrum of COL2A1 and further elucidate the genotype-phenotype relationships in the East Asian populations with STL1, which is poorly studied at present.By searching MEDLINE, Web of Science, CNKI, Wanfang Data, HGMD and Clinvar, all publications associated with STL1 were collected. Then, they were carefully screened to obtain all reported STL1-related variants in COL2A1 and clinical features in East Asian patients with STL1.There were 274 COL2A1 variants identified in 999 patients with STL1 from 466 unrelated families, and more than half of them were truncation mutations. Of the 107 STL1 patients reported in the East Asian population, it was found that patients with truncation mutations had milder systemic phenotypes, whereas patients with splicing mutations had severer phenotypes. In addition, several recurrent variants (c.3106C>T, c.1833+1G>A, c.2710C>T and c.1693C>T) were found.Genotype-phenotype correlations should certainly be studied carefully, contributed to making personalized follow-up plans and predicting prognosis of this disorder. Genome editing holds great potential for treating inherited diseases caused by pathogenic mutations. In this study, several recurrent variants were found, providing potential candidate targets for genetic manipulation in the future.

Visit link:
Mutation Spectrum of Stickler Syndrome Type I and Genotype-phenotype Analysis in East Asian Population: a systematic review. - Physician's Weekly

Read More...

This cancer treatment gives patients night-vision, and we finally know why – Big Think

Friday, February 14th, 2020

In the early 2000s, it was reported that a certain kind of skin cancer treatment called photodynamic therapy, which uses light to destroy malignant cells, had a bizarre side effect: It was giving patients enhanced night time vision.

Rods and cones photoreceptors in a human retina.

Photo Credit: Dr. Robert Fariss, National Eye Institute, NIH / Flickr

"Seeing" happens when a series of receptors in the retina, the cones and rods, collect light. Rods contain a lot of rhodopsin, a photosensitive protein that absorbs visible light thanks to an active compound found in it called retinal. When retinal is exposed to visible light, it splits from rhodopsin. This then allows the light signal to be converted into an electrical signal that the visual cortex of our brains interprets into sight. Of course, there is "less light" at night, which actually means that light radiation is not in a domain visible to humans. It's at higher wavelengths (the infrared level) that retinal is not sensitive to. Hence, why we can't see in the dark like many critters can.

But the vision process can be activated by another interaction of light and chemistry. As it turns out, a chlorin e6 injection under infrared light changes retinal in the same way that visible light does. This is the cause of the unforeseen night vision side effect of the treatment.

"Molecular simulation" is a method that uses an algorithm that integrates the laws of quantum and Newtonian physics to model the functioning of a biological system over time. The team used this method to mimic the biomechanical movements of individual atoms that is, their attraction or repulsion to one another along with the making or breaking of chemical bonds.

"For our simulation we placed a virtual rhodopsin protein inserted in its lipid membrane in contact with several chlorin e6 molecules and water, or several tens of thousands of atoms," Monari explained to CNRS. "Our super-calculators ran for several months and completed millions of calculations before they were able to simulate the entire biochemical reaction triggered by infrared radiation." In nature, this phenomena occurs within fractions of a nanosecond.

The molecular simulation showed that when the chlorin e6 molecule absorbs the infrared radiation, it interacts with the oxygen present in the eye tissue and transforms it into reactive, or singlet, oxygen. In addition to killing cancer cells, "singlet oxygen" can also react with retinal to enable a slightly enhanced eyesight at night, when light waves are at the infrared level.

Now that researchers know why the "supernatural" side effect occurs, they may be able to limit the chance of it happening to patients undergoing photodynamic treatment. Thinking further out, the researchers hope for the possibility that this chemical reaction could be harnessed to help treat certain types of blindness and sensitivity to light.

Ultimately, researchers say that this has been a big flex for the power of molecular simulations, which can give us astonishing scientific insights like this.

"Molecular simulation is already being used to shed light on fundamental mechanisms for example, why certain DNA lesions are better repaired than others and enable the selection of potential therapeutic molecules by mimicking their interaction with a chosen target," Monari told CNRS.

Related Articles Around the Web

Read more here:
This cancer treatment gives patients night-vision, and we finally know why - Big Think

Read More...

Page 32«..1020..31323334..4050..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick